Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Top Page
Ascendis Pharma
(NASDAQ:ASND)
Rating:61Neutral
Price Target:
$205.00
▼(-0.11% Downside)
Positive Factors
Financial Performance
Yorvipath revenues beat company-compiled consensus by about 33%.
Market Penetration
A significant increase in U.S. Yorvipath prescriptions suggests a rapid uptake since launch announcement.
Regulatory Approval
The approval of Yorvipath in Japan highlights its profile as a differentiated treatment for HPT, supporting positive sentiment towards the company's prospects.
Negative Factors
Market Competition
Yorvipath's clinical benefit and strong potential to maintain a favorable market position despite emerging competition are highlighted.
Sales Performance
Sales of Skytrofa were reported at €50.7M, which was below consensus estimates of €63.2M/€58.9M, suggesting weaker market performance.
Ascendis Pharma (ASND) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.47B
Dividend YieldN/A
Average Volume (3M)513.80K
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue Growth55.77%
EPS Growth46.81%
CountryUS
Employees1,017
SectorHealthcare
Sector Strength52
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.96
Shares Outstanding61,151,463
10 Day Avg. Volume396,891
30 Day Avg. Volume513,796
Financial Highlights & Ratios
PEG Ratio0.86
Price to Book (P/B)-72.81
Price to Sales (P/S)21.17
P/FCF Ratio-25.02
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue34.69
Enterprise Value/Gross Profit40.26
Enterprise Value/Ebitda-63.58
Forecast
1Y Price Target
$250.44Price Target Upside22.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Ascendis Pharma Business Overview & Revenue Model
Company DescriptionAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
How the Company Makes MoneyAscendis Pharma generates revenue through the commercialization of its pharmaceutical products, primarily focusing on therapies developed using its TransCon technology. Key revenue streams include sales from its approved products, such as TransCon Growth Hormone, and potential royalties from product sales by partners. The company also engages in strategic collaborations and licensing agreements with other biopharmaceutical firms, which can provide upfront payments, milestone payments upon achieving development goals, and ongoing royalties based on future sales. Significant partnerships can enhance Ascendis Pharma's financial stability and growth prospects by expanding its market reach and leveraging the expertise of established players in the industry.
Ascendis Pharma Key Performance Indicators (KPIs)
Any
External Customers Revenue by Type
Analyzes revenue streams from different customer segments, highlighting which areas drive sales and indicating potential growth opportunities or risks based on customer diversification.
Analyzes revenue streams from different customer segments, highlighting which areas drive sales and indicating potential growth opportunities or risks based on customer diversification.
Data provided by:
Main Street Data
Main Street DataAscendis Pharma Earnings Call Summary
Earnings Call Date:Aug 07, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 13, 2025
Earnings Call Sentiment Positive
The earnings call reflected a strong performance for Ascendis Pharma with significant revenue growth, successful product launches, and strategic progress in their pipeline. While there are challenges related to currency impacts and patient conversion timelines, these are offset by the momentum in product adoption and regulatory advancements.Q2-2025 Updates
Positive Updates
Strong Revenue Growth for YORVIPATH
YORVIPATH revenue in Q2 reached EUR 103 million, more than double from Q1 2025, with strong U.S. uptake and continued international growth.
FDA Approval and Expansion for SKYTROFA
SKYTROFA received FDA approval for adult growth hormone deficiency, with Q2 revenue of EUR 51 million, and plans for further label expansion.
Priority Review for TransCon CNP
FDA granted priority review for TransCon CNP with a PDUFA date of November 30, recognizing its potential to significantly improve treatment for achondroplasia.
Progress in Combination Therapy for Achondroplasia
Interim Phase II results showed a boost in linear growth and body proportionality improvement in achondroplasia patients using a combination of TransCon CNP and TransCon Growth Hormone.
Strong Financial Position
Total Q2 product revenue was EUR 153.7 million, with expectations for Ascendis to become cash flow positive on a quarterly basis this year.
Negative Updates
Currency Headwinds Impact Revenue
A negative sequential foreign currency exchange rate impact of EUR 7.6 million affected Q2 total product revenue.
Challenges in Patient Enrollment and Conversion
The time from enrollment to patient conversion for YORVIPATH is approximately 3 months, with ongoing efforts to improve this timeline.
Increase in SG&A Expenses
SG&A expenses in Q2 2025 increased to EUR 107.6 million from EUR 74.3 million in the same period last year, driven by global commercial expansion.
Company Guidance
During the Q2 2025 earnings call for Ascendis Pharma, the company provided several financial and strategic updates. Revenue for the second quarter reached EUR 153.7 million, with YORVIPATH contributing EUR 103 million, more than doubling from Q1 despite currency headwinds. SKYTROFA generated EUR 50.7 million in revenue, with a negative currency impact of EUR 1.8 million. The company highlighted the strong launch of YORVIPATH, with over 3,100 unique patients receiving prescriptions from more than 1,500 prescribers in the U.S. and noted high payer approval rates within three months. Ascendis expects YORVIPATH to become a blockbuster product, with plans to expand its market presence and leverage strategic partnerships. Additionally, Ascendis reported a decrease in R&D expenses to EUR 72 million and an increase in SG&A expenses to EUR 107.6 million, driven by global commercial expansion. The company ended the quarter with cash and cash equivalents totaling EUR 494 million, expecting to become cash flow positive on a quarterly basis this year.Ascendis Pharma Financial Statement Overview
Summary
Ascendis Pharma shows significant revenue growth, but faces challenges with profitability and financial stability. The company operates at a loss with negative margins and relies heavily on debt financing, posing potential risks.Income Statement
Ascendis Pharma shows significant revenue growth with a Revenue Growth Rate of 36.3% from 2023 to 2024. However, the company continues to operate at a loss, with negative Gross Profit Margin and Net Profit Margin due to substantial R&D expenses typical in biotechnology. EBIT and EBITDA margins remain negative, indicating ongoing operating losses.45
Neutral
Balance Sheet
The company's financial structure is concerning, with negative Stockholders' Equity indicating accumulated losses. The Debt-to-Equity Ratio is not calculable due to negative equity, highlighting potential financial instability. The Equity Ratio is also negative, reflecting the company's reliance on debt financing.30
Negative
Cash Flow
Operating Cash Flow remains negative, reflecting cash outflows from operations. However, Free Cash Flow improved slightly year-over-year, though it remains negative. The Free Cash Flow to Net Income Ratio is not favorable. There is a reliance on financing activities to support cash needs.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 310.87M | 363.64M | 266.72M | 51.17M | 7.78M | 6.95M |
| Gross Profit | 267.86M | 319.38M | 222.32M | 39.04M | 4.25M | 6.95M |
| EBITDA | -169.64M | -290.02M | -411.17M | -529.18M | -364.64M | -407.81M |
| Net Income | -242.47M | -378.08M | -481.45M | -583.19M | -383.58M | -418.95M |
Balance Sheet | ||||||
| Total Assets | 1.06B | 1.18B | 825.59M | 1.09B | 1.08B | 979.79M |
| Cash, Cash Equivalents and Short-Term Investments | 517.92M | 559.54M | 399.44M | 735.46M | 682.06M | 718.79M |
| Total Debt | 847.27M | 856.62M | 743.06M | 617.57M | 209.92M | 91.97M |
| Total Liabilities | 1.25B | 1.29B | 971.28M | 826.39M | 201.29M | 141.08M |
| Stockholders Equity | -189.81M | -105.71M | -145.70M | 263.35M | 883.63M | 838.71M |
Cash Flow | ||||||
| Free Cash Flow | -164.22M | -307.62M | -469.80M | -510.19M | -441.88M | -293.10M |
| Operating Cash Flow | -162.80M | -306.20M | -467.36M | -495.70M | -417.65M | -271.55M |
| Investing Cash Flow | -479.00K | 6.88M | 286.47M | 61.73M | -110.58M | -291.20M |
| Financing Cash Flow | -20.39M | 443.93M | 134.29M | 396.77M | 351.39M | 602.65M |
Ascendis Pharma Technical Analysis
Positive
205.22
Price Trends
182.86
Positive
174.35
Positive
157.32
Positive
Market Momentum
5.52
Negative
66.98
Neutral
78.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASND, the sentiment is Positive. The current price of 205.22 is above the 20-day moving average (MA) of 195.93, above the 50-day MA of 182.86, and above the 200-day MA of 157.32, indicating a bullish trend. The MACD of 5.52 indicates Negative momentum. The RSI at 66.98 is Neutral, neither overbought nor oversold. The STOCH value of 78.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASND.
Ascendis Pharma Risk Analysis
Ascendis Pharma disclosed 90 risk factors in its most recent earnings report. Ascendis Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ascendis Pharma Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $18.11B | 15.64 | 19.30% | ― | 17.62% | 19.89% | |
76 Outperform | $11.09B | 17.11 | 11.62% | ― | 17.38% | 153.58% | |
75 Outperform | $10.20B | 18.17 | 29.00% | ― | 10.73% | 81.66% | |
61 Neutral | $12.47B | ― | 357.68% | ― | 55.77% | 46.81% | |
58 Neutral | $10.20B | ― | 35.68% | ― | 7.62% | -55.29% | |
56 Neutral | $9.65B | ― | -36.30% | ― | 3421.98% | 49.62% | |
51 Neutral | $7.95B | -0.38 | -42.44% | 2.22% | 22.30% | -1.83% |
* Healthcare Sector Average
Performance Comparison
ASND
Ascendis Pharma
205.22
88.38
75.64%
BMRN
BioMarin Pharmaceutical
56.38
-27.95
-33.14%
EXEL
Exelixis
37.69
12.18
47.75%
MDGL
Madrigal Pharmaceuticals
453.80
215.11
90.12%
UTHR
United Therapeutics
394.62
45.91
13.17%
BBIO
BridgeBio Pharma
54.29
23.59
76.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.